Rationale for and clinical development of anti-fractalkine antibody in rheumatic diseases

References

• Bryant VL, Slade CA. Chemokines, their receptors and human disease: the good, the bad and the itchy. Immunol Cell Biol. 2015;93(4):364–371.
   PubMed Web of Science ®Google Scholar
• Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385(6617):640–644.
   PubMed Web of Science ®Google Scholar
• Nomiyama H, Osada N, Yoshie O. The evolution of mammalian chemokine genes. Cytokine Growth Factor Rev. 2010;21(4):253–262.
   PubMed Web of Science ®Google Scholar
• Nomiyama H, Osada N, Yoshie O. A family tree of vertebrate chemokine receptors for a unified nomenclature. Dev Comp Immunol. 2011;35(7):705–715.
   PubMed Web of Science ®Google Scholar
• Yoshie O, Imai T, Nomiyama H. Chemokines in immunity. Adv Immunol. 2001;78:57–110.
   PubMed Web of Science ®Google Scholar
• Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91(4):521–530.
   PubMed Web of Science ®Google Scholar
• Kim KW, Vallon-Eberhard A, Zigmond E, et al. In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. Blood. 2011;118(22):e156–67.
   PubMed Web of Science ®Google Scholar
• Garton KJ, Gough PJ, Blobel CP, et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem. 2001;276(41):37993–38001.
   PubMed Web of Science ®Google Scholar
• Tsou CL, Haskell CA, Charo IF. Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem. 2001;276(48):44622–44626.
   PubMed Web of Science ®Google Scholar
• Düsterhöft S, Lokau J, Garbers C. The metalloprotease ADAM17 in inflammation and cancer. Pathol Res Pract. 2019 Jun;215(6):152410.
   PubMed Web of Science ®Google Scholar
• Italiani P, Boraschi DCP. From monocytes to m1/m2 macrophages: phenotypical vs. functional differentiation. Front Immunol. 2014;5:514.
   PubMed Web of Science ®Google Scholar
• Nishimura M, Umehara H, Nakayama T, et al. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol. 2002;168(12):6173–6180.
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116(16):e74–80.
   PubMed Web of Science ®Google Scholar
• Ancuta P, Rao R, Moses A, et al. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med. 2003;197(12):1701–1707.
   PubMed Web of Science ®Google Scholar
• Wong KL, Tai JJ, Wong WC, et al. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood. 2011;118(5):e16–31.
   PubMed Web of Science ®Google Scholar
• Kawamura S, Ohteki T. Monopoiesis in humans and mice. Int Immunol. 2018 Oct 29;30(11):503–509.
   PubMed Web of Science ®Google Scholar
• Arazi A, Rao DA, Berthier CC, et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019 Jul;20(7):902–914.
   PubMed Web of Science ®Google Scholar
• Chanouzas D, Dyall L, Dale J, et al. CD4+CD28- T-cell expansions in ANCA-associated vasculitis and association with arterial stiffness: baseline data from a randomised controlled trial. Lancet. 2015 Feb 26;385(Suppl 1):S30.
   PubMedGoogle Scholar
• Chanouzas D, Sagmeister M, Dyall L, et al. The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis. Arthritis Res Ther. 2018 Aug 29;20(1):194.
   PubMed Web of Science ®Google Scholar
• Morgan MD, Pachnio A, Begum J, et al. CD4+CD28- T cell expansion in granulomatosis with polyangiitis (Wegener’s) is driven by latent cytomegalovirus infection and is associated with an increased risk of infection and mortality. Arthritis Rheum. 2011 Jul;63(7):2127–2137.
   PubMed Web of Science ®Google Scholar
• Rao DA, Gurish MF, Marshall JL, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2019 Feb 1;542(7639):110–114.
   Web of Science ®Google Scholar
• Sawai H, Park YW, Roberson J, et al. T cell costimulation by fractalkine-expressing synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2005;52(5):1392–1401.
   PubMed Web of Science ®Google Scholar
• Goda S, Imai T, Yoshie O, et al. CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol. 2000;164(8):4313–4320.
   PubMed Web of Science ®Google Scholar
• Hundhausen C, Misztela D, Berkhout TA, et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood. 2003;102(4):1186–1195.
   PubMed Web of Science ®Google Scholar
• Umehara H, Bloom ET, Okazaki T, et al. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol. 2004;24(1):34–40.
   PubMed Web of Science ®Google Scholar
• Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007;317(5838):666–670.
   PubMed Web of Science ®Google Scholar
• Carlin LM, Stamatiades EG, Auffray C, et al. Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell. 2013;153(2):362–375.
   PubMed Web of Science ®Google Scholar
• Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19(1):71–82.
   PubMed Web of Science ®Google Scholar
• Hoshino A, Ueha S, Hanada S, et al. Roles of chemokine receptor CX3CR1 in maintaining murine bone homeostasis through the regulation of both osteoblasts and osteoclasts. J Cell Sci. 2013;126(Pt 4):1032–1045.
   PubMed Web of Science ®Google Scholar
• Koizumi K, Saitoh Y, Minami T, et al. Role of CX3CL1/fractalkine in osteoclast differentiation and bone resorption. J Immunol. 2009;183(12):7825–7831.
   PubMed Web of Science ®Google Scholar
• Matsuura T, Ichinose S, Akiyama M, et al. Involvement of CX3CL1 in the Migration of Osteoclast Precursors Across Osteoblast Layer Stimulated by Interleukin-1ss. J Cell Physiol. 2017;232(7):1739–1745.
   PubMed Web of Science ®Google Scholar
• Isozaki T, Kasama T, Takahashi R, et al. Synergistic induction of CX3CL1 by TNF alpha and IFN gamma in osteoblasts from rheumatoid arthritis: involvement of NF-kappa B and STAT-1 signaling pathways. J Inflamm Res. 2008;1:19–28.
   PubMedGoogle Scholar
• Lionakis MS, Swamydas M, Fischer BG, et al. CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J Clin Invest. 2013;123(12):5035–5051.
   PubMed Web of Science ®Google Scholar
• White GE, Greaves DR. Fractalkine: a survivor’s guide: chemokines as antiapoptotic mediators. Arterioscler Thromb Vasc Biol. 2012;32(3):589–594.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219.
   PubMed Web of Science ®Google Scholar
• Brennan FM, McInnes IBCP. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118(11):3537–3545.
   PubMed Web of Science ®Google Scholar
• Arts EE, Fransen J, Den Broeder AA, et al. Low disease activity (DAS28</=3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. Ann Rheum Dis. 2017;76(10):1693–1699.
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Chandran A, Ilhan B, et al. The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis. 2016;75(3):560–565.
   PubMed Web of Science ®Google Scholar
• Orr C, Vieira-Sousa E, Boyle DL, et al. Synovial tissue research: a state-of-the-art review. Nat Rev Rheumatol. 2017;13(8):463–475.
   PubMed Web of Science ®Google Scholar
• Smith MD, Barg E, Weedon H, et al. Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. Ann Rheum Dis. 2003;62(4):303–307.
   PubMed Web of Science ®Google Scholar
• Jones BA, Riegsecker S, Rahman A, et al. Role of ADAM-17, p38 MAPK, cathepsins, and the proteasome pathway in the synthesis and shedding of fractalkine/CX(3) CL1 in rheumatoid arthritis. Arthritis Rheum. 2013;65(11):2814–2825.
   PubMed Web of Science ®Google Scholar
• Nanki T, Imai T, Nagasaka K, et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum. 2002;46(11):2878–2883.
   PubMed Web of Science ®Google Scholar
• Ruth JH, Volin MV, Haines GK 3rd, et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum. 2001;44(7):1568–1581.
   PubMed Web of Science ®Google Scholar
• Matsunawa M, Isozaki T, Odai T, et al. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum. 2006;54(11):3408–3416.
   PubMed Web of Science ®Google Scholar
• Umemura M, Isozaki T, Ishii S, et al. Reduction of Serum ADAM17 Level Accompanied with Decreased Cytokines after Abatacept Therapy in Patients with Rheumatoid Arthritis. Int J Biomed Sci. 2014;10(4):229–235.
   PubMedGoogle Scholar
• Yano R, Yamamura M, Sunahori K, et al. Recruitment of CD16+ monocytes into synovial tissues is mediated by fractalkine and CX3CR1 in rheumatoid arthritis patients. Acta Med Okayama. 2007 Apr;61(2):89–98.
   PubMed Web of Science ®Google Scholar
• Sawai H, Park YW, He X, et al. Fractalkine mediates T cell-dependent proliferation of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum. 2007 Oct;56(10):3215–3225.
   PubMed Web of Science ®Google Scholar
• Volin MV, Huynh N, Klosowska K, et al. Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Akt. Arthritis Rheum. 2007;56(8):2512–2522.
   PubMed Web of Science ®Google Scholar
• Mizoguchi F, Slowikowski K, Wei K, et al. Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nat Commun. 2018;9(1):789.
   PubMed Web of Science ®Google Scholar
• Blaschke S, Koziolek M, Schwarz A, et al. Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis. J Rheumatol. 2003 Sep;30(9):1918–1927.
   PubMed Web of Science ®Google Scholar
• Nanki T, Urasaki Y, Imai T, et al. Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J Immunol. 2004;173(11):7010–7016.
   PubMed Web of Science ®Google Scholar
• Hoshino-Negishi K, Ohkuro M, Nakatani T, et al. Role of Anti-Fractalkine Antibody in Suppression of Joint Destruction by Inhibiting Migration of Osteoclast Precursors to the Synovium in Experimental Arthritis. Arthritis Rheumatol. 2019;71(2):222–231.
   PubMed Web of Science ®Google Scholar
• Volin MV, Woods JM, Amin MA, et al. Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol. 2001;159(4):1521–1530.
   PubMed Web of Science ®Google Scholar
• Odai T, Matsunawa M, Takahashi R, et al. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis. J Rheumatol. 2009;36(6):1158–1165.
   PubMed Web of Science ®Google Scholar
• Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62–68.
   PubMed Web of Science ®Google Scholar
• Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690–1697.
   PubMed Web of Science ®Google Scholar
• Sakai R, Hirano F, Kihara M, et al. High prevalence of cardiovascular comorbidities in patients with rheumatoid arthritis from a population-based cross-sectional study of a Japanese health insurance database. Mod Rheumatol. 2016 Jul;26(4):522–528.
   PubMed Web of Science ®Google Scholar
• Apostolakis S, Spandidos D. Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway. Acta Pharmacol Sin. 2013 Oct;34(10):1251–1256.
   PubMed Web of Science ®Google Scholar
• Butoi ED, Gan AM, Manduteanu I, et al. Cross talk between smooth muscle cells and monocytes/activated monocytes via CX3CL1/CX3CR1 axis augments expression of pro-atherogenic molecules. Biochim Biophys Acta. 2011 Dec;1813(12):2026–2035.
   PubMed Web of Science ®Google Scholar
• Combadiere C, Potteaux S, Gao JL, et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation. 2003 Feb 25;107(7):1009–1016.
   PubMed Web of Science ®Google Scholar
• Lesnik P, Haskell CA, Charo IFCP. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest. 2003;111(3):333–340.
   PubMed Web of Science ®Google Scholar
• Pingiotti E, Cipriani P, Marrelli A, et al. Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28 T cells in RA patients and correlation with atherosclerotic damage. Ann N Y Acad Sci. 2007;1107:32–41.
   PubMed Web of Science ®Google Scholar
• Hoshino-Negishi K, Ohkuro M, Nakatani T, et al. Anti-Fractalkine Monoclonal Antibody Inhibits Joint Destruction through Suppression of Osteoclast Precursor Migration and Induces Synovial Cell Death in Collagen-Induced Arthritis Model Mice [abstract]. Arthritis Rheumatol. 2018;70(suppl):10.
   Google Scholar
• Tanaka Y, Takeuchi T, Umehara H, et al. Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. Mod Rheumatol. 2018;28(1):58–65.
   PubMed Web of Science ®Google Scholar
• Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039.
   PubMed Web of Science ®Google Scholar
• Sato E, Iikuni N, Yoshio T, et al. Soluble fractalkine in the cerebrospinal fluid of patients with neuropsychiatric lupus. Ann Rheum Dis. 2006;65(9):1257–1259.
   PubMed Web of Science ®Google Scholar
• Yajima N, Kasama T, Isozaki T, et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum. 2005;52(6):1670–1675.
   PubMed Web of Science ®Google Scholar
• You Y, Qin Y, Lin X, et al. Upregulated fractalkine levels in Chinese patients with lupus nephritis. Cytokine. 2018;104:23–28.
   PubMed Web of Science ®Google Scholar
• Danila MI, Pons-Estel GJ, Zhang J, et al. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford). 2009;48(5):542–545.
   PubMed Web of Science ®Google Scholar
• Almaani S, Meara A, Rovin BHCP. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017;12(5):825–835.
   PubMed Web of Science ®Google Scholar
• Yoshimoto S, Nakatani K, Iwano M, et al. Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis. Am J Kidney Dis. 2007;50(1):47–58.
   PubMed Web of Science ®Google Scholar
• Nakatani K, Yoshimoto S, Iwano M, et al. Fractalkine expression and CD16+ monocyte accumulation in glomerular lesions: association with their severity and diversity in lupus models. Am J Physiol Renal Physiol. 2010;299(1):F207–16.
   PubMed Web of Science ®Google Scholar
• Inoue A, Hasegawa H, Kohno M, et al. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum. 2005;52(5):1522–1533.
   PubMed Web of Science ®Google Scholar
• Lan L, Han F, Lang X, et al. Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses. PLoS One. 2016;11(7):e0159964.
   PubMed Web of Science ®Google Scholar
• Guo L, Lu X, Wang Y, et al. Elevated levels of soluble fractalkine and increased expression of CX3CR1 in neuropsychiatric systemic lupus erythematosus. Exp Ther Med. 2017;14(4):3153–3158.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Sato S, Echigo T, et al. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis. 2005;64(1):21–28.
   PubMed Web of Science ®Google Scholar
• Luong VH, Utsunomiya A, Chino T, et al. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX3 CL1/CX3 CR1 Pathway in Experimental Mouse Models of Systemic Sclerosis. Arthritis Rheumatol. 2019 Nov;71(11):1923–1934.
   PubMed Web of Science ®Google Scholar
• Arai M, Ikawa Y, Chujo S, et al. Chemokine receptors CCR2 and CX3CR1 regulate skin fibrosis in the mouse model of cytokine-induced systemic sclerosis. J Dermatol Sci. 2013;69(3):250–258.
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold AM, Weigt SS, Palchevskiy V, et al. Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis. PLoS One. 2018;13(11):e0206545.
   PubMed Web of Science ®Google Scholar
• Elias JA, Freundlich B, Kern JA, et al. Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest. 1990;97(6):1439–1445.
   PubMed Web of Science ®Google Scholar
• Isozaki T, Otsuka K, Sato M, et al. Synergistic induction of CX3CL1 by interleukin-1beta and interferon-gamma in human lung fibroblasts: involvement of signal transducer and activator of transcription 1 signaling pathways. Transl Res. 2011;157(2):64–70.
   PubMed Web of Science ®Google Scholar
• Ishida Y, Kimura A, Nosaka M, et al. Essential involvement of the CX3CL1-CX3CR1 axis in bleomycin-induced pulmonary fibrosis via regulation of fibrocyte and M2 macrophage migration. Sci Rep. 2017;7(1):16833.
   PubMed Web of Science ®Google Scholar
• Engel DR, Krause TA, Snelgrove SL, et al. CX3CR1 reduces kidney fibrosis by inhibiting local proliferation of profibrotic macrophages. J Immunol. 2015;194(4):1628–1638.
   PubMed Web of Science ®Google Scholar
• Peng X, Zhang J, Xiao Z, et al. CX3CL1-CX3CR1 Interaction Increases the Population of Ly6C(-)CX3CR1(hi) Macrophages Contributing to Unilateral Ureteral Obstruction-Induced Fibrosis. J Immunol. 2015;195(6):2797–2805.
   PubMed Web of Science ®Google Scholar
• Shimizu K, Furuichi K, Sakai N, et al. Fractalkine and its receptor, CX3CR1, promote hypertensive interstitial fibrosis in the kidney. Hypertens Res. 2011;34(6):747–752.
   PubMed Web of Science ®Google Scholar
• Wasmuth HE, Zaldivar MM, Berres ML, et al. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol. 2008;48(2):208–215.
   PubMed Web of Science ®Google Scholar
• Suzuki F, Nanki T, Imai T, et al. Inhibition of CX3CL1 (fractalkine) improves experimental autoimmune myositis in SJL/J mice. J Immunol. 2005;175(10):6987–6996.
   PubMed Web of Science ®Google Scholar
• Suzuki F, Kubota T, Miyazaki Y, et al. Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity. Arthritis Res Ther. 2012;14(2):R48.
   PubMed Web of Science ®Google Scholar
• Nishimi A, Isozaki T, Nishimi S, et al. ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease. Clin Rheumatol. 2018;37(4):1017–1024.
   PubMed Web of Science ®Google Scholar
• Yajima N, Wakabayashi K, Odai T, et al. Clinical features of hemophagocytic syndrome in patients with dermatomyositis. J Rheumatol. 2008;35(9):1838–1841.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Aoki A, Asakawa K, et al. Cytokine profiles of amyopathic dermatomyositis with interstitial lung diseases treated with mycophenolate. Respirol Case Rep. 2017;5(4):e00235.
   PubMed Web of Science ®Google Scholar
• Takada T, Aoki A, Asakawa K, et al. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis. Respir Med. 2015;109(9):1174–1180.
   PubMed Web of Science ®Google Scholar
• Tsubota K, Nishiyama T, Mishima K, et al. The role of fractalkine as an accelerating factor on the autoimmune exocrinopathy in mice. Invest Ophthalmol Vis Sci. 2009;50(10):4753–4760.
   PubMed Web of Science ®Google Scholar
• Wildenberg ME, van Helden-meeuwsen CG, Drexhage HA, et al. Altered fractalkine cleavage potentially promotes local inflammation in NOD salivary gland. Arthritis Res Ther. 2008;10(3):R69.
   PubMed Web of Science ®Google Scholar
• Astorri E, Scrivo R, Bombardieri M, et al. CX3CL1 and CX3CR1 expression in tertiary lymphoid structures in salivary gland infiltrates: fractalkine contribution to lymphoid neogenesis in Sjogren’s syndrome. Rheumatology (Oxford). 2014;53(4):611–620.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kwok SK, Jung SM, et al. Role of fractalkine in the pathogenesis of primary Sjogren syndrome: increased serum levels of fractalkine, its expression in labial salivary glands, and the association with clinical manifestations. J Rheumatol. 2014;41(12):2425–2438.
   PubMed Web of Science ®Google Scholar
• Imgenberg-Kreuz J, Sandling JK, Bjork A, et al. Transcription profiling of peripheral B cells in antibody-positive primary Sjogren’s syndrome reveals upregulated expression of CX3CR1 and a type I and type II interferon signature. Scand J Immunol. 2018;87(5):e12662.
   PubMed Web of Science ®Google Scholar
• Andreasson U, Ek S, Merz H, et al. B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. Cancer Lett. 2008 Feb 8;259(2):138–145.
   PubMed Web of Science ®Google Scholar
• Corcione A, Ferretti E, Bertolotto M, et al. CX3CR1 is expressed by human B lymphocytes and mediates [corrected] CX3CL1 driven chemotaxis of tonsil centrocytes. PLoS One. 2009;4(12):e8485.
   PubMed Web of Science ®Google Scholar
• Deutsch AJ, Aigelsreiter A, Steinbauer E, et al. Distinct signatures of B-cell homeostatic and activation-dependent chemokine receptors in the development and progression of extragastric MALT lymphomas. J Pathol. 2008 Aug;215(4):431–444.
   PubMed Web of Science ®Google Scholar
• Ferretti E, Pistoia V, Corcione A. Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies. Mediators Inflamm. 2014;2014:480941.
   PubMed Web of Science ®Google Scholar
• Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjogren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006 Jun;65(6):796–803.
   PubMed Web of Science ®Google Scholar
• Wojdasiewicz P, Poniatowski LA, Kotela A, et al. The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1: occurrence and potential role in osteoarthritis. Arch Immunol Ther Exp (Warsz). 2014;62(5):395–403.
   PubMed Web of Science ®Google Scholar
• Hou SM, Hou CH, Liu JFCP. CX3CL1 promotes MMP-3 production via the CX3CR1, c-Raf, MEK, ERK, and NF-kappaB signaling pathway in osteoarthritis synovial fibroblasts. Arthritis Res Ther. 2017;19(1):282.
   PubMed Web of Science ®Google Scholar
• Zou Y, Li Y, Lu L, et al. Correlation of fractalkine concentrations in serum and synovial fluid with the radiographic severity of knee osteoarthritis. Ann Clin Biochem. 2013;50(Pt 6):571–575.
   PubMed Web of Science ®Google Scholar
• Gomez-Aristizabal A, Gandhi R, Mahomed NN, et al. Synovial fluid monocyte/macrophage subsets and their correlation to patient-reported outcomes in osteoarthritic patients: a cohort study. Arthritis Res Ther. 2019;21(1):26.
   PubMed Web of Science ®Google Scholar
• Huo LW, Ye YL, Wang GW, et al. Fractalkine (CX3CL1): a biomarker reflecting symptomatic severity in patients with knee osteoarthritis. J Investig Med. 2015;63(4):626–631.
   PubMed Web of Science ®Google Scholar
• Klosowska K, Volin MV, Huynh N, et al. Fractalkine functions as a chemoattractant for osteoarthritis synovial fibroblasts and stimulates phosphorylation of mitogen-activated protein kinases and Akt. Clin Exp Immunol. 2009;156(2):312–319.
   PubMed Web of Science ®Google Scholar
• Sun Y, Wang F, Sun X, et al. CX3CR1 regulates osteoarthrosis chondrocyte proliferation and apoptosis via Wnt/beta-catenin signaling. Biomed Pharmacother. 2017;96:1317–1323.
   PubMed Web of Science ®Google Scholar
• Zhao L, Wang Q, Zhang C, et al. Genome-wide DNA methylation analysis of articular chondrocytes identifies TRAF1, CTGF, and CX3CL1 genes as hypomethylated in osteoarthritis. Clin Rheumatol. 2017;36(10):2335–2342.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.
   PubMed Web of Science ®Google Scholar
• Cockwell P, Chakravorty SJ, Girdlestone J, et al. Fractalkine expression in human renal inflammation. J Pathol. 2002;196(1):85–90.
   PubMed Web of Science ®Google Scholar
• Matsunawa M, Odai T, Wakabayashi K, et al. Elevated serum levels of soluble CX3CL1 in patients with microscopic polyangiitis. Clin Exp Rheumatol. 2009;27(1):72–78.
   PubMed Web of Science ®Google Scholar
• Bjerkeli V, Damas JK, Fevang B, et al. Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener’s granulomatosis–possible role in vascular inflammation. Rheumatology (Oxford). 2007;46(9):1422–1427.
   PubMed Web of Science ®Google Scholar
• Morimura S, Sugaya M, Sato S. Interaction between CX3CL1 and CX3CR1 regulates vasculitis induced by immune complex deposition. Am J Pathol. 2013;182(5):1640–1647.
   PubMed Web of Science ®Google Scholar
• Chen T, Guo ZP, Jiao XY, et al. CCL5, CXCL16, and CX3CL1 are associated with Henoch-Schonlein purpura. Arch Dermatol Res. 2011;303(10):715–725.
   PubMed Web of Science ®Google Scholar
• Kasama T, Wakabayashi K, Sato M, et al. Relevance of the CX3CL1/fractalkine-CX3CR1 pathway in vasculitis and vasculopathy. Transl Res. 2010;155(1):20–26.
   PubMed Web of Science ®Google Scholar
• Tabuchi H, Katsurabara T, Mori M, et al. Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study. J Clin Pharmacol. 2018;59(5):688–701.
   PubMed Web of Science ®Google Scholar
• Jin Y, Kang EH, Brill G, et al. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. J Rheumatol. 2018;45(9):1240–1248.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xie F, Yun H, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1813–1818.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Gerardi MC, Barilaro G, et al. Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. Expert Rev Clin Immunol. 2018;14(1):69–82.
   PubMed Web of Science ®Google Scholar
• Benyamine A, Magalon J, Cointe S, et al. Increased serum levels of fractalkine and mobilisation of CD34(+)CD45(-) endothelial progenitor cells in systemic sclerosis. Arthritis Res Ther. 2017;19(1):60.
   PubMed Web of Science ®Google Scholar